Monitoring and Management of IgM Levels with Kesimpta

Introduction to Kesimpta Treatment

The Blood Cancer Journal recommends regular monitoring of immunoglobulin levels during Kesimpta treatment, with particular attention to IgM and IgG levels 1
Monthly monitoring of Ig levels is recommended if immunoglobulin replacement therapy is initiated, as suggested by the Blood Cancer Journal 1

Low IgM levels increase the risk of infections, particularly with encapsulated bacteria, according to the Blood Cancer Journal 1
Consider immunoglobulin replacement therapy for patients who have experienced ≥2 severe recurrent infections by encapsulated bacteria, regardless of IgG level, as recommended by the Blood Cancer Journal 1, 2
Monthly IVIG treatment is recommended for the duration of immunoparesis until Ig levels recover, as suggested by the Blood Cancer Journal 2

IgG and IgM serology tests for diagnosis of viral infections may be used routinely but should be interpreted with caution in patients on Kesimpta, according to the Blood Cancer Journal 1
Patients may have false negative results in response to IgG and IgM serology tests due to failure to mount antibody responses to pathogens, as noted by the Blood Cancer Journal 1

Kesimpta dosing should be maintained during immunoglobulin replacement therapy, as recommended by the Blood Cancer Journal 2
Consider discontinuing Kesimpta if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, although this is not directly cited, the approach is implied through management strategies 2